Feasibility 'innate' allogeneic stem cells transplantion

Towards a novel immune therapy platform with an innate allogeneic haematopoietic stem cell transplantation in patients with haematological malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25484

Enrollment

Registered

2015-02-19

Start date

2015-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies (hematologische maligniteiten) Allogeneic stem cells transplantation (allogene stamcel transplantatie) Innate immune system (aangeboren immuunsysteem)

Interventions

Reduced toxicity myeloablative conditioning regime, alpha beta T-cell depleted stem cell graft.

Eligibility

Inclusion criteria

Inclusion criteria: Adults Haematological malignancies eligible to allo-SCT WHO performance status ≤ 2 Written informed consent

Exclusion criteria

Exclusion criteria: Relapse of allo-SCT within 6 months after allo-SCT Bilirubin and/or transaminases > 2.5 x normal value Creatinine clearance < 40 ml/min Cardiac dysfunction as defined by (Unstable angina; Unstable cardiac arrhythmias) Active, uncontrolled infection

Design outcomes

Primary

Measure	Time frame
Incidence of aGVHD at day 100.	—

Secondary

Measure	Time frame
Treatment related mortality (TRM) at day 100 Donor engraftment (chimerism > 95%) at day 100	—

Contacts

Public ContactJ Kuball

KC02.085.2

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)